XM does not provide services to residents of the United States of America.
A
A

ACADIA

News

U.S. Duolingo, Nova, Universal Health Services

U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services Aug 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Duolingo, Nova and Universal Health Services, on Friday. HIGHLIGHTS * Duolingo Inc DUOL.O : Goldman Sachs raises to neutral from sell * Eventbrite Inc EB.N : Piper Sandler cuts to neutral from overweight * HCA Healthcare Inc HCA.N : JP Morgan raises target price to $379 from $332 * Nova Ltd NVMI.O : E
A
A

U.S. Amphastar Pharmaceuticals, G1 Therapeutics, Upwork

U.S. RESEARCH ROUNDUP-Amphastar Pharmaceuticals, G1 Therapeutics, Upwork Aug 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amphastar Pharmaceuticals, G1 Therapeutics and Upwork on Thursday. HIGHLIGHTS * Amphastar Pharmaceuticals Inc AMPH.O : Piper Sandler cuts target price to $66 from $71 * Charles River Laboratories International Inc CRL.N : Baird cuts to neutral * G1 Therapeutics Inc GTHX.O : H.C.
A
A
C
G
A
C
I

U.S. Amgen, Atkore, MoneyLion

U.S. RESEARCH ROUNDUP-Amgen, Atkore, MoneyLion Aug 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Atkore and MoneyLion on Wednesday. HIGHLIGHTS * Amgen Inc AMGN.O : RBC raises target price to $362 from $332 * Atkore Inc ATKR.N : RBC cuts to sector perform from outperform * MoneyLion ML.N : Needham cuts target price to $70 from $100 * Progyny Inc PGNY.O : BTIG cuts to neutral from buy * Truecar Inc TRUE.O :
A
A
A
B
B

Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18

BRIEF-Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18 Aug 06 (Reuters) - Acadia Pharmaceuticals Q2 product sales USD 241.963 million vs. IBES estimate USD 235.4 million. Q2 pretax profit USD 37.182 million vs. IBES estimate USD 32.1 million Q2 net income USD 33.389 million vs. IBES estimate USD 31.1 million Q2 operating expenses US
A

ACADIA Pharmaceuticals Inc <ACAD.OQ> expected to post earnings of 18 cents a share - Earnings Preview

ACADIA Pharmaceuticals Inc expected to post earnings of 18 cents a share - Earnings Preview ACADIA Pharmaceuticals Inc ACAD.OQ ACAD.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2024 The San Diego California-based company is expected to report a 42.5% increase in revenue to $235.418 million from $165.24 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.